Patent application number | Description | Published |
20090060870 | METHODS AND MEANS FOR THE TREATMENT OF HPV INDUCED INTRAEPITHELIAL NEOPLASIA - The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response. | 03-05-2009 |
20090220534 | METHODS FOR IDENTIFYING T-CELL EPITOPES ASSOCIATED WITH IMPAIRED PEPTIDE PROCESSING AND APPLICATIONS OF THE IDENTIFIED EPITOPES - The current invention provides methods for the identification of antigens and/or epitopes that are differentially displayed on TAP deficient or TAP impaired cells and are not detectably displayed on normal or TAP proficient cells. The identification and applications of these differentially presented antigens, which in this specification are referred to as TEIPP, T cell Epitopes associated with Impaired Peptide Processing, is a prime object of this invention. The invention also provides peptides comprising a TEIPP epitope obtained from the methods of the invention, which may be applied in medicaments and methods of treatment raising a T cell response against TAP deficient tumor cells or virally infected cells. | 09-03-2009 |
20100120683 | Prame derived peptides and immunogenic compositions comprising these - The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer. | 05-13-2010 |
20100189742 | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines - The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B. | 07-29-2010 |
20100196353 | INTRADERMAL HPV PEPTIDE VACCINATION - The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration. | 08-05-2010 |
20110008287 | METHODS AND MEANS FOR THE TREATMENT OF HPV INDUCED INTRAEPITHELIAL NEOPLASIAS - The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the anogenital tract, such as HPV induced vulvar, cervical, vaginal, penile and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+ response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response. | 01-13-2011 |
20140348862 | Prame derived peptides and immunogenic compositions comprising these - The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer. | 11-27-2014 |
Patent application number | Description | Published |
20110311525 | DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT - The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease, wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph node of a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered. | 12-22-2011 |
20120315304 | SENSITIZATION OF IMMUNE SYSTEM AGAINST HAPTENIZED MELANOMA ANTIGENS - The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies. | 12-13-2012 |
20130071428 | PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE - The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease. | 03-21-2013 |